Elizabeth L. Seashore, MD
Department or Service
Location
- Texas Medical Center
Specialty
Phone: 832-822-4242
Contact Information
Research Laboratory
Research Area
- Cancer
- Leukemia
Clinical Fellow, Department of Pediatrics, Section of Hematology-Oncology, Baylor College of Medicine
Education
| School | Education | Degree | Year |
|---|---|---|---|
| Boston University School of Medicine | medical school | Doctor of Medicine | 2013 |
| Brandeis University | bachelors | Bachelor of Science, Biology and Philosophy | 2006 |
| NY-Presbyterian Hospital, Columbia University Medical Center | residency | Pediatrics | 2016 |
About
Dr. Elizabeth Seashore started her pediatric hematology/oncology fellowship training in 2016. Dr. Seashore first developed a passion for oncology as a clinical research coordinator in adult blood cancers at the University of California, San Francisco, prior to medical school. Her love of caring for children drew her to pediatric oncology, where she is as excited by the science of cancer as she is inspired by her incredible patients and their families.
As a pediatric hematology and oncology fellow, Dr. Seashore treats a wide variety of blood diseases and cancers. She is specifically interested in pediatric leukemia.
She believes in not only providing the very best cancer treatment for each individual child, but also ensuring excellent quality of life, and plans to pursue additional training in palliative care after her fellowship.
Board Certifications
American Board of Pediatrics
Organization
| Organization Name | Role |
|---|---|
| American Academy of Pediatrics (AAP) | Member |
| American Society of Hematology (ASH) | Member |
| American Society of Pediatric Hematology/Oncology (ASPHO) | Member |
| Children's Oncology Group (COG) | Member |
Research Statement
Dr. Seashore's current research interests include advancing the understanding of pediatric blood cancers, specifically acute myeloid leukemia (AML). She is conducting laboratory research aimed at identifying unique characteristics of leukemia stem cells, which can be resistant to standard chemotherapy and cause relapse. She hopes that her findings can ultimately be used to eliminate these stem cells with targeted therapies.